Potassium citrate

Identification

Summary

Potassium citrate is an agent used to manage renal tubular acidosis, hypocitraturic calcium oxalate nephrolithiasis, and uric acid lithiasis with or without calcium stones.

Brand Names
Cytra-K, Urocit-K
Generic Name
Potassium citrate
DrugBank Accession Number
DB09125
Background

Potassium citrate (also known as tripotassium citrate) is a potassium salt of citric acid. It is a white, hygroscopic crystalline powder. It is odorless with a saline taste. It contains 38.3% potassium by mass. In the monohydrate form it is highly hygroscopic and deliquescent. Potassium citrate is used to treat a kidney stone condition called renal tubular acidosis. Potassium Citrate is indicated also for the management of Hypocitraturic calcium oxalate nephrolithiasis.

Type
Small Molecule
Groups
Approved, Investigational, Vet approved
Structure
Weight
Average: 306.394
Monoisotopic: 305.89464697
Chemical Formula
C6H5K3O7
Synonyms
  • Potassium citrate anhydrous
  • Tripotassium citrate

Pharmacology

Indication

For the management of renal tubular acidosis, hypocitraturic calcium oxalate nephrolithiasis, and uric acid lithiasis with or without calcium stones.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination to treatAcidosis, renal tubularCombination Product in combination with: Citric acid (DB04272), Sodium citrate (DB09154)••• ••••••••
Used in combination for therapyBowel preparation therapyCombination Product in combination with: Potassium bicarbonate (DB11098)•••••••••••••••••••• ••••••••••••
Used in combination to treatConstipationCombination Product in combination with: Potassium bicarbonate (DB11098)•••••••••••••••••••• ••••••••••••
Treatment ofHypocitraturic calcium oxalate nephrolithiasis••••••••••••
Management ofHypocitraturic calcium oxalate nephrolithiasis••••••••••••
Associated Therapies
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Potassium citrate induces changes in the urine which renders urine less susceptible to the formation of crystals and stones from salts e.g. calcium oxalate, calcium phosphate and uric acid. Increased citrate levels in the urine will make complexation with calcium which decrease the calcium ion activity and decrease the chance for the formation of calcium phosphate crystals. Citrate also inhibits the spontaneous nucleation of calcium oxalate and calcium phosphate.

Mechanism of action

After oral administration of potassium citrate, its metabolism yields alkaline load. Potassium Citrate therapy appears to increase urinary citrate mainly by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. In addition to raising urinary pH and citrate, Potassium Citrate increases urinary potassium by approximately the amount contained in the medication. In some patients, Potassium Citrate causes a transient reduction in urinary calcium.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Potassium Citrate is absorbed and the citrate is metabolised to bicarbonate.

Route of elimination

Urinary; less than 5% unchanged.

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

LD50 (dog): Intravenous 176 mg/kg.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirPotassium citrate may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.
AcebutololPotassium citrate may increase the hyperkalemic activities of Acebutolol.
AceclofenacPotassium citrate may increase the excretion rate of Aceclofenac which could result in a lower serum level and potentially a reduction in efficacy.
AcemetacinThe therapeutic efficacy of Potassium citrate can be decreased when used in combination with Acemetacin.
AcetaminophenPotassium citrate may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy.
Food Interactions
  • Take with food. Take potassium citrate within 30 minutes of eating to limit gastrointestinal irritation.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Potassium citrate monohydrateEE90ONI6FF6100-05-6PJAHUDTUZRZBKM-UHFFFAOYSA-K
Active Moieties
NameKindUNIICASInChI Key
Potassium cationionic295O53K15224203-36-9NPYPAHLBTDXSSS-UHFFFAOYSA-N
Citric acidunknownXF417D3PSL77-92-9KRKNYBCHXYNGOX-UHFFFAOYSA-N
Product Images
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Polycitra-KSolution398 mg / 5 mLOralJanssen Pharmaceuticals1996-12-312009-10-02Canada flag
Polycitra-KPowder1.193 g / 4.5 gOralAlza1996-12-312001-08-01Canada flag
Potassium CitrateTablet10 meq/1OralUpsher-Smith Laboratories, LLC2006-09-01Not applicableUS flag
Potassium CitrateTablet5 meq/1OralUpsher-Smith Laboratories, LLC2006-09-01Not applicableUS flag
Urocit-KTablet, extended release540 mgOralMission Pharmacal Company1995-01-01Not applicableCanada flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Potassium CitrateTablet, extended release540 mg/1OralMed-Health Pharma, LLC.2011-04-102012-04-25US flag
Potassium CitrateTablet, extended release15 meq/1OralActavis Pharma, Inc.2018-05-30Not applicableUS flag
Potassium CitrateTablet, extended release10 meq/1Oralbryant ranch prepack2020-03-16Not applicableUS flag
Potassium CitrateTablet, extended release15 meq/1OralAscent Pharmaceuticals Inc2021-02-15Not applicableUS flag
Potassium CitrateTablet, extended release15 meq/1OralZydus Pharmaceuticals (USA) Inc.2014-08-12Not applicableUS flag
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
CITRAL SYRUP (PLAIN) 500 mg/5 mlSyrup500 mg/5mlOralSINGAPORE PHARMACEUTICAL PRIVATE LIMITED1991-09-16Not applicableSingapore flag
K Lyte Tab Lime & Orange FlavTablet, effervescent975 mg / tabOralBristol Labs Division Of Bristol Myers Squibb1965-12-311997-08-14Canada flag
Potassium 99mg TabletsTablet99 mg / tabOralBioforce Canada Inc.1994-12-311997-04-14Canada flag
Potassium Tab 99mgTablet99 mg / tabOralDa Vinci Laboratories, Division Of Foodscience Corporation1981-12-311997-05-08Canada flag
Prime's Mixture Potassium CitrateSyrupOralPRIME PHARMACEUTICAL SDN. BHD.2020-09-08Not applicableMalaysia flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
B 6 PlusPotassium citrate (50 mg) + Magnesium oxide (50 mg) + Niacin (20 mg) + Pyridoxine (50 mg) + Riboflavin (2.4 mg) + Thiamine (10 mg)TabletOralAnabolic Laboratories Inc.1967-12-312004-03-15Canada flag
B6 Plus TabPotassium citrate (50 mg) + Magnesium oxide (50 mg) + Niacin (20 mg) + Pyridoxine hydrochloride (50 mg) + Riboflavin (2.4 mg) + Thiamine (10 mg)TabletOralVita Health Products Inc1979-12-312002-08-01Canada flag
BIOCHETASIPotassium citrate (1.06 mg) + Cocarboxylase (47 mg) + Riboflavin-5'-phosphate sodium salt dihydrate (28 mg) + Pyridoxine hydrochloride (15 mg) + Sodium citrate (56 mg)Injection, solutionIntramuscularAlfasigma s.p.a.2014-07-082020-10-13Italy flag
BIOCHETASIPotassium citrate (50 mg) + Citric acid (100 mg) + Cocarboxylase (50 mg) + Riboflavin-5'-phosphate sodium salt dihydrate (25 mg) + Pyridoxine hydrochloride (12.5 mg) + Sodium citrate (425 mg)Granule, effervescentOralAlfasigma s.p.a.2019-10-31Not applicableItaly flag
BIOCHETASIPotassium citrate (50 mg) + Citric acid (70 mg) + Cocarboxylase (50 mg) + Riboflavin 5'-phosphate sodium anhydrous (25 mg) + Pyridoxine hydrochloride (12.5 mg) + Sodium citrate (425 mg)Tablet, effervescentOralAlfasigma s.p.a.2014-07-08Not applicableItaly flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Cytra 3Potassium citrate monohydrate (550 mg/5mL) + Citric acid monohydrate (334 mg/5mL) + Sodium citrate (500 mg/5mL)SyrupOralCypress Pharmaceuticals, Inc2008-07-292014-10-11US flag
Cytra 3Potassium citrate monohydrate (550 mg/5mL) + Citric acid monohydrate (334 mg/5mL) + Sodium citrate (500 mg/5mL)SyrupOralPegasus Laboratories2006-05-052009-10-17US flag
Cytra-KPotassium citrate monohydrate (1100 mg/5mL) + Citric acid monohydrate (334 mg/5mL)SolutionOralCypress Pharmaceutical, Inc.2008-09-302014-10-11US flag
Cytra-K CrystalsPotassium citrate monohydrate (3.3 g/1) + Citric acid monohydrate (1.002 g/1)Granule, for solutionOralCypress Pharmaceutical, Inc.2003-05-01Not applicableUS flag
Lab 52 Essential Oil SensitivePotassium citrate monohydrate (5.53 g/100g) + Sodium fluoride (0.32 g/100g)Paste, dentifriceDentalTOOTHFILM INC2022-05-07Not applicableUS flag

Categories

ATC Codes
A12BA02 — Potassium citrate
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as tricarboxylic acids and derivatives. These are carboxylic acids containing exactly three carboxyl groups.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Tricarboxylic acids and derivatives
Direct Parent
Tricarboxylic acids and derivatives
Alternative Parents
Tertiary alcohols / Carboxylic acid salts / Carboxylic acids / Organic potassium salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Alcohol / Aliphatic acyclic compound / Carbonyl group / Carboxylic acid / Carboxylic acid salt / Hydrocarbon derivative / Organic alkali metal salt / Organic oxide / Organic oxygen compound / Organic potassium salt
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
potassium salt (CHEBI:64733)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
86R1NVR0HW
CAS number
866-84-2
InChI Key
QEEAPRPFLLJWCF-UHFFFAOYSA-K
InChI
InChI=1S/C6H8O7.3K/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;3*+1/p-3
IUPAC Name
tripotassium 2-hydroxypropane-1,2,3-tricarboxylate
SMILES
[K+].[K+].[K+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O

References

General References
  1. Monograph [Link]
  2. safety data sheet [Link]
PubChem Compound
13344
PubChem Substance
310265041
ChemSpider
12775
RxNav
54993
ChEBI
64733
ChEMBL
CHEMBL1200458
Wikipedia
Potassium_citrate
FDA label
Download (81.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentDuodenal Ulcer Due to Helicobacter Pylori1
4CompletedTreatmentHypersensitivity Dentin / Periodontal Disease1
4CompletedTreatmentHypertension1
4CompletedTreatmentKidney Stones / Urolithiasis1
4CompletedTreatmentMetabolic Bone Disorder / Postmenopausal Osteoporosis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral
Injection, powder, for solutionIntramuscular
Injection, solutionIntramuscular
SuppositoryRectal
CapsuleOral
SyrupOral500 mg/5ml
Granule, for solutionOral
Tablet, film coated
PowderOral
Tablet, effervescentOral975 mg / tab
Powder, for solutionOral
GranuleOral2157.3 mg
SyrupOral
TabletOral
Paste, dentifriceDental
AerosolDental
LiquidOral
SolutionOral
Granule, effervescentOral
PowderOral1.193 g / 4.5 g
SolutionOral398 mg / 5 mL
Tablet, effervescentOral
TabletOral99 mg / tab
TabletOral15 meq/1
TabletOral5 meq/1
Tablet, extended releaseOral10 meq/1
Tablet, extended releaseOral1080 mg/1
Tablet, extended releaseOral15 meq/1
Tablet, extended releaseOral5 meq/1
Tablet, extended releaseOral540 mg/1
TabletOral10 meq/1
SolutionOral5 % w/v
For solutionOral
SolutionOral200 mg/5ml
SyrupOral3 g/10ml
SyrupOral
Tablet, extended releaseOral1080 mg
Tablet, extended releaseOral540 mg
Tablet, extended releaseOral
TabletOral540 mg
Tablet, extended releaseOral108000000 mg
Drug delivery systemOral
Syrup
SolutionNasal
TabletOral1080 mg
Tablet
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility39.4 mg/mLALOGPS
logP-0.7ALOGPS
logP-1.3Chemaxon
logS-0.89ALOGPS
pKa (Strongest Acidic)3.05Chemaxon
pKa (Strongest Basic)-4.2Chemaxon
Physiological Charge-3Chemaxon
Hydrogen Acceptor Count7Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area140.62 Å2Chemaxon
Rotatable Bond Count5Chemaxon
Refractivity68.14 m3·mol-1Chemaxon
Polarizability14.23 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0a4i-0009000000-1c9c5a3c5c210234aa14
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-127.92728
predicted
DeepCCS 1.0 (2019)
[M+H]+130.01086
predicted
DeepCCS 1.0 (2019)
[M+Na]+135.92238
predicted
DeepCCS 1.0 (2019)

Drug created at September 23, 2015 16:41 / Updated at March 18, 2024 16:48